OCA
NAMS icon

Octagon Capital Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

Octagon Capital Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-408,000
Closed -$9.65M – 54
2024
Q1 		$9.65M Buy
+408,000
New +$8.28M 1.16% 25

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Octagon Capital Advisors's NAMS Position: Q2 2024 in Review

Octagon Capital Advisors sold out of NewAmsterdam Pharma (NAMS) in Q2 2024, closing a stake of 408,000 shares — an estimated $9.65M sold.

Octagon Capital Advisors first reported a position in NAMS in Q1 2024 and held it in 1 quarter. The position peaked at $9.65M in Q1 2024. 90 funds tracked by Wall St. Rank hold NAMS as of Q2 2024.

  • Octagon Capital Advisors reported no remaining NewAmsterdam Pharma position as of Q2 2024 after selling out during the quarter.
  • Octagon Capital Advisors sold 408,000 NewAmsterdam Pharma shares in Q2 2024, an estimated $9.65M.
  • Octagon Capital Advisors first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 1 quarter.
  • Octagon Capital Advisors's NewAmsterdam Pharma position peaked at $9.65M in Q1 2024.
  • 90 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2024.

Based on Octagon Capital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.